Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer. Issue 10 (7th June 2021)

• Record Type: Journal Article
• Authors: Igarashi, Chika; Yoshii, Yukie; Tashima, Hideaki; Iwao, Yuma; Sakurai, Kohei; Hihara, Fukiko; Tachibana, Tomoko; Yoshida, Eiji; Wakizaka, Hidekatsu; Akamatsu, Go; Yamaya, Taiga; Yoshimoto, Mitsuyoshi; Matsumoto, Hiroki; Zhang, Ming-Rong; Nagatsu, Kotaro; Sugyo, Aya; Tsuji, Atsushi B.; Higashi, Tatsuya
• Is Part Of: Nuclear medicine communications. Volume 42:Issue 10(2021)
• Page Start: 1112
• Page End: 1121
• Publication Date: 2021-06-07
• Subjects: 64Cu-labeled cetuximab -- OpenPET -- pancreatic cancer -- PET-guided surgery; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000001442
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Background: In pancreatic cancer surgery, accurate identification and resection of intrapancreatic residual tumors are quite difficult. We have developed a novel open-typed PET system (called 'OpenPET'), which enables high-resolution PET-guided surgery in real time, and demonstrated that OpenPET-guided surgery with intraperitoneally administered 64 Cu-labeled anti-epidermal growth factor receptor antibody cetuximab is useful to detect and resect primary pancreatic cancer. Here, we investigated applicability of OpenPET-guided surgery for unexpected residual intrapancreatic tumors and examined its survival benefit over conventional surgery. Methods: A mouse model with large (>1 cm) resectable pancreatic cancer of xPA-1-DC cells expressing red fluorescent protein was used. OpenPET-guided surgery was conducted 24 h after intraperitoneal administration of 64 Cu-labeled cetuximab (7.4 MBq/mouse). For comparison, similar surgical procedures were conducted, and conventional tumor resection was attempted using only the naked eye (control). Survival rate after OpenPET-guided surgery was compared to that after control operations. Results: Intraoperative OpenPET guidance enabled detection and resection of small residual tumors. Ten residual tumor specimens (3–10 mm in diameter) were intraoperatively isolated with OpenPET guidance ( n = 7 mice). All isolated specimens showed tumor RFP signals. No resection of tumor tissue was performed in control group because the tumor could not be clearly detected with the naked eye alone. Mice after OpenPET-guided surgery showed significantly longer survival rates than those in control group. Conclusions: OpenPET-guided surgery with 64 Cu-labeled-cetuximab enabled intraoperative identification and resection of intrapancreatic small residual tumors. This technology could be useful to prevent tumor residuals during surgery and improve pancreatic cancer survival.